Randomised controlled trial (n=30) assessing IV ketamine 0.5 mg/kg (2 weekly infusions) versus IV scopolamine 4 µg/kg and saline placebo as add-on treatment in patients with major depressive disorder.
Randomised, interventional Phase II/III study of intravenous ketamine 0.5 mg/kg given once weekly for two weeks as an adjunctive treatment in patients with major depressive disorder on stable oral antidepressants.
Comparators include intravenous scopolamine 4 µg/kg (weekly for two weeks) and saline placebo; outcomes include change in MADRS and CGI at baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.
Intravenous ketamine 0.5 mg/kg given once weekly for two weeks as add-on to antidepressant therapy.
Infusion given once per week for 2 weeks (2 sessions).
Intravenous scopolamine 4 µg/kg given once weekly for two weeks as active comparator.
Scopolamine 4 µg/kg infusion once per week for 2 weeks.
Intravenous saline placebo infusion.
Saline placebo infusion once; comparator/placebo arm.